Gyre Therapeutics, Inc. Increase (Decrease) in Other Receivables
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Other Receivables of $96.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2025-03-17
- Gyre Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2023-12-31 was -$1.10M.
- Gyre Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2014-03-31 was $64.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2013-03-31 was -$997.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other receivables for fiscal 2023 was $96.00K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|
| 2023-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $96.00K 10-K · filed 2025-03-17 | |
| 2023-09-30 | $1.20M 10-Q · filed 2023-10-26 | ||
| 2014-03-31 | $64.00K 10-Q · filed 2014-05-08 | ||
| 2013-09-30 | -$322.00K 10-Q · filed 2013-11-06 | ||
| 2013-03-31 | -$997.00K 10-Q · filed 2014-05-08 | ||
| 2012-09-30 | $2.33M 10-Q · filed 2013-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |